CYYNF (Cynata Therapeutics) 1-Year Share Buyback Ratio: -5.40% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cynata Therapeutics 1-Year Share Buyback Ratio?

Cynata Therapeutics CYYNF 1-Year Share Buyback Ratio is -5.40 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 1,116 Biotechnology companies, Cynata Therapeutics ranks better than 63.62% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Cynata Therapeutics's current 1-Year Share Buyback Ratio was -5.40%.

CYYNF's 1-Year Share Buyback Ratio is ranked better than
63.62% of 1116 companies
in the Biotechnology industry
Industry Median: -13.25 vs CYYNF: -5.40

Cynata Therapeutics  (OTCPK:CYYNF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Cynata Therapeutics 1-Year Share Buyback Ratio Related Terms

CYYNF vs VRTX, REGN, RVMD: 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Cynata Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cynata Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's 1-Year Share Buyback Ratio falls into.


Cynata Therapeutics 1-Year Share Buyback Ratio Calculation

Cynata Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2024 ) - Shares Outstanding (EOP) (Dec. 2025 )) / Shares Outstanding (EOP) (Dec. 2024 )
=(225.246 - 237.454) / 225.246
=-5.4%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -5.40 mean?
Cynata Therapeutics (CYYNF) has a 1-Year Share Buyback Ratio of -5.40 as of Dec. 2025. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Cynata Therapeutics and its competitors. According to the industry distribution chart, Cynata Therapeutics ranks #406 out of 1116 companies in the Biotechnology industry, placing it in the top 36.4%.
Is Cynata Therapeutics' 1-Year Share Buyback Ratio too high?
Cynata Therapeutics' current 1-Year Share Buyback Ratio is -5.40. Based on the distribution chart, Cynata Therapeutics ranks #406 out of 1116 companies in the Biotechnology industry, which is above the industry midpoint.
How does Cynata Therapeutics' 1-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cynata Therapeutics ranks #406 out of 1116 companies for 1-Year Share Buyback Ratio. This puts Cynata Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Cynata Therapeutics and its competitors. Cynata Therapeutics's current 1-Year Share Buyback Ratio is -5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current 1-Year Share Buyback Ratio of -5.40. The current 1-Year Share Buyback Ratio is -5.40. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current 1-Year Share Buyback Ratio is -5.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.